English
Back
Open Account
2026 IPO bonanza! Over 90% of new stocks rose on their debut!
牛牛新股君
joined discussion · May 5 10:01 ·

IPO News | 'The First AI Drug Delivery Stock' JiTai Technology launches its IPO, scheduled to list on May 13, with a minimum subscription amount of HKD 5,302.95

Futu Information reported on May 5 that $METIS TECHBIO-P (07666.HK)$ An announcement was made for the IPO period from May 5 to May 8. The company plans to offer approximately 201,229,000 shares globally and is expected to be listed on May 13.
Futu Information reported on May 5 that $METIS TECHBIO-P (07666.HK)$ An announcement was made for the IPO period from May 5 to May 8. The company plans to offer approximately 201,229,000 shares globally and is expected to be listed on May 13. Company Overview JiTai Technology is an AI-driven biotech company specializing in material development and technological innovation for drug nanodelivery. The company has independently developed NanoForge, the world's first AI-powered drug nanodelivery platform. NanoForge can reduce the formulation R&D time for small molecule drugs from 1-2 years to 3 months and achieve precise drug delivery targeting eight organs or tissues such as the liver, muscle, tumors, and immune system. Based on this, the company accelerates the development of innovative therapies in critical disease areas through both independent research and collaboration. As of the latest practicable date, the company has more than 10 pipeline products, with the fastest one reaching the pre-NDA stage. Meanwhile, the company has established new drug R&D collaborations with over 30 pharmaceutical and biotech companies worldwide. Financial Summary From 2023 to 2025, JiTai Technology's revenues were RMB 9.338 million, RMB 1.482 million, and RMB 105 million respectively, with nearly 70 times growth in 2025 primarily driven by the upfront payment of RMB 100 million from the out-licensing of MTS-004...
Company Overview
JiTai Technology is an AI-driven biotech company specializing in material development and technological innovation for drug nanodelivery. The company has independently developed NanoForge, the world's first AI-powered drug nanodelivery platform. NanoForge can reduce the formulation R&D time for small molecule drugs from 1-2 years to 3 months and achieve precise drug delivery targeting eight organs or tissues such as the liver, muscle, tumors, and immune system. Based on this, the company accelerates the development of innovative therapies in critical disease areas through both independent research and collaboration.
As of the latest practicable date, the company has more than 10 pipeline products, with the fastest one reaching the pre-NDA stage. Meanwhile, the company has established new drug R&D collaborations with over 30 pharmaceutical and biotech companies worldwide.
Financial Summary
From 2023 to 2025, JiTai Technology's revenues were RMB 9.338 million, RMB 1.482 million, and RMB 105 million respectively, with nearly 70 times growth in 2025 primarily driven by the upfront payment of RMB 100 million from the out-licensing of MTS-004. The gross margins for 2023, 2024, and 2025 were 59.8%, 55.5%, and 98.2% respectively. Meanwhile, the adjusted net losses were RMB 350 million, RMB 240 million, and RMB 180 million, showing continuous improvement in operational efficiency.
Futu Information reported on May 5 that $METIS TECHBIO-P (07666.HK)$ An announcement was made for the IPO period from May 5 to May 8. The company plans to offer approximately 201,229,000 shares globally and is expected to be listed on May 13. Company Overview JiTai Technology is an AI-driven biotech company specializing in material development and technological innovation for drug nanodelivery. The company has independently developed NanoForge, the world's first AI-powered drug nanodelivery platform. NanoForge can reduce the formulation R&D time for small molecule drugs from 1-2 years to 3 months and achieve precise drug delivery targeting eight organs or tissues such as the liver, muscle, tumors, and immune system. Based on this, the company accelerates the development of innovative therapies in critical disease areas through both independent research and collaboration. As of the latest practicable date, the company has more than 10 pipeline products, with the fastest one reaching the pre-NDA stage. Meanwhile, the company has established new drug R&D collaborations with over 30 pharmaceutical and biotech companies worldwide. Financial Summary From 2023 to 2025, JiTai Technology's revenues were RMB 9.338 million, RMB 1.482 million, and RMB 105 million respectively, with nearly 70 times growth in 2025 primarily driven by the upfront payment of RMB 100 million from the out-licensing of MTS-004...
Use of Proceeds
In terms of the use of proceeds, Ji Tai Technology expects the net proceeds from the global offering to be approximately HKD 1,976.9 million (assuming the over-allotment option is not exercised, based on an offer price of HKD 10.50). According to the prospectus, Ji Tai Technology intends to allocate the proceeds from the global offering for the following purposes in the specified amounts:
Approximately 50.0% will be used to support core technology research, development, and advancement in the company’s AI infrastructure and AI-driven nanomaterials platform; approximately 20.0% will be allocated to ongoing and planned clinical trials within the company’s AI-developed product pipeline, advancing candidate drugs across multiple therapeutic areas and modalities; approximately 10.0% will be used to develop the company’s animal health and anti-aging solutions, expanding AI-powered solutions into these high-growth areas; approximately 10.0% will be allocated to support the company's growth strategy in building an AI-driven nanomaterials ecosystem globally; and approximately 10.0% will be used as working capital and for other general corporate purposes.
Further reading:Jitai Technology's Prospectus
The golden season for new stock subscriptions has arrived! Use Futu for new stock subscriptions—zero interest, zero handling fees, and zero cash subscription. Participants now have the chance to have their new stock subscription fees waived for a year.Come and experience it now >>
Futu Information reported on May 5 that $METIS TECHBIO-P (07666.HK)$ An announcement was made for the IPO period from May 5 to May 8. The company plans to offer approximately 201,229,000 shares globally and is expected to be listed on May 13. Company Overview JiTai Technology is an AI-driven biotech company specializing in material development and technological innovation for drug nanodelivery. The company has independently developed NanoForge, the world's first AI-powered drug nanodelivery platform. NanoForge can reduce the formulation R&D time for small molecule drugs from 1-2 years to 3 months and achieve precise drug delivery targeting eight organs or tissues such as the liver, muscle, tumors, and immune system. Based on this, the company accelerates the development of innovative therapies in critical disease areas through both independent research and collaboration. As of the latest practicable date, the company has more than 10 pipeline products, with the fastest one reaching the pre-NDA stage. Meanwhile, the company has established new drug R&D collaborations with over 30 pharmaceutical and biotech companies worldwide. Financial Summary From 2023 to 2025, JiTai Technology's revenues were RMB 9.338 million, RMB 1.482 million, and RMB 105 million respectively, with nearly 70 times growth in 2025 primarily driven by the upfront payment of RMB 100 million from the out-licensing of MTS-004...
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
Thumbs Up
17
119K Views
Report
Comments (4)
Write a Comment...
4
17
189